Cargando…

Conditional Survival in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab

BACKGROUND: Nivolumab is approved for the treatment of advanced renal cell carcinoma (RCC). However, traditional overall survival (OS) or progression-free survival (PFS) do not reflect patient prognosis after initial management. Therefore, this study aimed to evaluate conditional overall survival (C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shao, Ning, Wan, Fangning, Zhu, Yao, Ye, Dingwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2019
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738006/ https://www.ncbi.nlm.nih.gov/pubmed/31469816 http://dx.doi.org/10.12659/MSM.916984

Ejemplares similares

Causes of Death and Conditional Survival of Renal Cell Carcinoma
por: Shao, Ning, et al.
Publicado: (2019)

Conditional disease-free survival in high-risk renal cell carcinoma treated with sunitinib
por: Shao, Ning, et al.
Publicado: (2019)

Prognostic value of D-lactate dehydrogenase in patients with clear cell renal cell carcinoma
por: Wang, Yue, et al.
Publicado: (2018)

Prognostic significance of the dynamic changes of systemic inflammatory response in metastatic renal cell carcinoma
por: Wang, Beihe, et al.
Publicado: (2019)

Upregulation of COL6A1 is predictive of poor prognosis in clear cell renal cell carcinoma patients
por: Wan, Fangning, et al.
Publicado: (2015)

ADIPOQ polymorphism rs182052 is associated with clear cell renal cell carcinoma
por: Zhang, Guiming, et al.
Publicado: (2015)

Identification and validation of soluble carrier family expression signature for predicting poor outcome of renal cell carcinoma
por: Fangning, Wan, et al.
Publicado: (2017)

A novel gene signature to predict immune infiltration and outcome in patients with prostate cancer
por: Shao, Ning, et al.
Publicado: (2020)

Serum Adiponectin Level May be an Independent Predictor of Clear Cell Renal Cell Carcinoma
por: Wang, Hongkai, et al.
Publicado: (2016)

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2022)

Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States
por: McCrea, Charles, et al.
Publicado: (2018)

Construction and Validation of a 9-Gene Signature for Predicting Prognosis in Stage III Clear Cell Renal Cell Carcinoma
por: Wu, Junlong, et al.
Publicado: (2019)

Development and validation of lncRNAs-based nomogram for prediction of biochemical recurrence in prostate cancer by bioinformatics analysis
por: Shao, Ning, et al.
Publicado: (2019)

Comprehensive Analysis of BAP1 Somatic Mutation in Clear Cell Renal Cell Carcinoma to Explore Potential Mechanisms in Silico
por: Jin, Shengming, et al.
Publicado: (2018)

Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab
por: Brown, Landon C., et al.
Publicado: (2021)

Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2
por: Gill, David M, et al.
Publicado: (2016)

Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)
por: Okada, Morihito, et al.
Publicado: (2022)

Nutritional screening is strongly associated with overall survival in patients treated with targeted agents for metastatic renal cell carcinoma
por: Gu, Weijie, et al.
Publicado: (2015)

Clinical outcome of advanced and metastatic renal cell carcinoma treated with targeted therapy: is there a difference between young and old patients?
por: Zhang, Guiming, et al.
Publicado: (2014)

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
por: Topalian, Suzanne L., et al.
Publicado: (2019)

Prognostic Value of Components of Body Composition in Patients Treated with Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Case Series
por: Gu, Weijie, et al.
Publicado: (2015)

FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy
por: Choueiri, Toni K, et al.
Publicado: (2022)

Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab
por: Nishikawa, Daisuke, et al.
Publicado: (2020)

Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma
por: Wiecek, Witold, et al.
Publicado: (2016)

Prognostic Value of Absolute Lymphocyte Count in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab plus Ipilimumab
por: Ueda, Kosuke, et al.
Publicado: (2023)

Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)
por: Atkins, Michael B, et al.
Publicado: (2023)

Vitiligo-like lesions in a patient treated with nivolumab for renal cell carcinoma
por: Lolli, Cristian, et al.
Publicado: (2018)

Modification of American Joint Committee on cancer prognostic groups for renal cell carcinoma
por: Shao, Ning, et al.
Publicado: (2018)

Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
por: Wang, Hao, et al.
Publicado: (2022)

m(6)A Regulator-Mediated Methylation Modification Model Predicts Prognosis, Tumor Microenvironment Characterizations and Response to Immunotherapies of Clear Cell Renal Cell Carcinoma
por: Xu, Wenhao, et al.
Publicado: (2021)

Fatty Acid Synthase Correlates With Prognosis-Related Abdominal Adipose Distribution and Metabolic Disorders of Clear Cell Renal Cell Carcinoma
por: Xu, Wenhao, et al.
Publicado: (2021)

Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study
por: Waddell, T., et al.
Publicado: (2022)

Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab
por: Noel, Johanna, et al.
Publicado: (2022)

A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630
por: Taniguchi, Yuri, et al.
Publicado: (2022)

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
por: Rini, Brian I, et al.
Publicado: (2022)

Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras
por: Li, Pengxiang, et al.
Publicado: (2015)

Analysis of adverse events of sunitinib in patients treated for advanced renal cell carcinoma
por: Domagała-Haduch, Małgorzata, et al.
Publicado: (2016)

Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma
por: Ye, Dingwei, et al.
Publicado: (2020)

Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma
por: Santini, Daniele, et al.
Publicado: (2016)

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
por: Fessas, Petros, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fdvf48fnbpjt6j5srbujem8gr4